周期蛋白依赖性激酶抑制剂fadraciclib(CYC065)耗竭抗凋亡蛋白并与venetoclax在原发性慢性淋巴细胞白血病细胞中协同作用
Fadraciclib(CYC065)是第二代氨基嘌呤CDK2/9抑制剂,对CDK2和CDK9的活性和选择性高于seliciclib。在原发性慢性淋巴细胞白血病(CLL)细胞中,fadraciclib抑制CDK9降低RNA聚合酶II C端结构域磷酸化并阻断转录,耗竭短寿命抗凋亡蛋白Mcl-1并诱导凋亡。模拟骨髓和淋巴结微环境可诱导Mcl-1表达并保护CLL细胞免于凋亡,但未延长Mcl-1周转率,fadraciclib有效消除该保护作用。Fadraciclib与Bcl-2拮抗剂venetoclax协同,尤其在17p缺失样本中诱导更深刻的CLL细胞死亡;两药同时维持时联合效果最佳。
要点
- Fadraciclib抑制CDK9阻断转录,耗竭Mcl-1并诱导CLL细胞凋亡。
- 模拟骨髓和淋巴结微环境未延长Mcl-1周转率,fadraciclib可消除其保护作用。
- Fadraciclib与venetoclax协同,在17p缺失样本中诱导更深刻的细胞死亡。
核心结论
- 本研究为fadraciclib单药或联合Bcl-2拮抗剂在CLL中的临床开发提供了依据。
研究设计与样本
- 本研究为体外研究,使用原发性慢性淋巴细胞白血病(CLL)细胞。
主要发现
- Fadraciclib抑制CDK9,降低RNA聚合酶II C端结构域磷酸化并阻断转录,耗竭Mcl-1并诱导凋亡。
- 模拟骨髓和淋巴结微环境诱导Mcl-1表达并保护CLL细胞免于凋亡,但未延长Mcl-1周转率,fadraciclib有效消除该保护作用。
- Fadraciclib与venetoclax协同,诱导更深刻的CLL细胞死亡,尤其在17p缺失样本中。
- Fadraciclib、venetoclax及联合用药的细胞死亡诱导动力学各异,但活性可逆,去除药物后未诱导额外细胞死亡。
- 两药同时维持时联合效果最佳。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fadraciclib (CYC065) is a second-generation aminopurine CDK2/9 inhibitor with increased potency and selectivity toward CDK2 and CDK9 compared to seliciclib (R-roscovitine). In chronic lymphocytic leukemia (CLL), a disease that depends on the over-expression of anti-apoptotic proteins for its survival, inhibition of CDK9 by fadraciclib reduced phosphorylation of the C-terminal domain of RNA polymerase II and blocked transcription in vitro; these actions depleted the intrinsically short-lived anti-apoptotic protein Mcl-1 and induced apoptosis. While the simulated bone marrow and lymph node microenvironments induced Mcl-1 expression and protected CLL cells from apoptosis, these conditions did not prolong the turnover rate of Mcl-1, and fadraciclib efficiently abrogated the protective effect. Further, fadraciclib was synergistic with the Bcl-2 antagonist venetoclax, inducing more profound CLL cell death, especially in samples with 17p deletion. While fadraciclib, venetoclax, and the combination each had distinct kinetics of cell death induction, their activities were reversible, as no additional cell death was induced upon removal of the drugs. The best combination effects were achieved when both drugs were maintained together. Altogether, this study provides a rationale for the clinical development of fadraciclib in CLL, either alone or in combination with a Bcl-2 antagonist.
引用
- Chen R, Chen Y, Xiong P, et al. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia. 2022. PMID: 35383271. doi:10.1038/s41375-022-01553-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。